Allergan nears $2.47B acquisition of ZELTIQ
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Allergan PLC's $2.47 billion purchase of ZELTIQ Aesthetics Inc. was cleared under U.S. antitrust laws.
The deal's waiting period under the Hart-Scott-Rodino Act expired, bringing the companies closer to completion.
The merger acquisition is still subject to other customer closing conditions.
